Inmune Bio (INMB) Debt to Equity (2021 - 2024)
Historic Debt to Equity for Inmune Bio (INMB) over the last 4 years, with Q3 2024 value amounting to $0.13.
- Inmune Bio's Debt to Equity fell 5416.17% to $0.13 in Q3 2024 from the same period last year, while for Sep 2024 it was $0.13, marking a year-over-year decrease of 5416.17%. This contributed to the annual value of $0.27 for FY2023, which is 865.65% up from last year.
- As of Q3 2024, Inmune Bio's Debt to Equity stood at $0.13, which was down 5416.17% from $0.28 recorded in Q2 2024.
- Inmune Bio's Debt to Equity's 5-year high stood at $0.53 during Q1 2024, with a 5-year trough of $0.13 in Q3 2024.
- In the last 4 years, Inmune Bio's Debt to Equity had a median value of $0.26 in 2023 and averaged $0.26.
- Over the last 5 years, Inmune Bio's Debt to Equity had its largest YoY gain of 9845.29% in 2024, and its largest YoY loss of 5416.17% in 2024.
- Over the past 4 years, Inmune Bio's Debt to Equity (Quarter) stood at $0.18 in 2021, then skyrocketed by 35.68% to $0.24 in 2022, then rose by 8.66% to $0.27 in 2023, then crashed by 51.4% to $0.13 in 2024.
- Its last three reported values are $0.13 in Q3 2024, $0.28 for Q2 2024, and $0.53 during Q1 2024.